PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)-Reference-Cited by-同舟云学术

PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)

Published:2011-12-18 Issue: Volume:Publish Ahead of Print Page:
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Stewart Michael W.,Rosenfeld Philip J.,Penha Fernando M.,Wang Fenghua,Yehoshua Zohar,Bueno-Lopez Elena,Lopez Pedro F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference20 articles.

1. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.;Ciulla;Curr Opin Ophthalmol,2009

2. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.;Ciulla;Curr Opin Ophthalmol,2009

3. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file.;Brechner;Am J Ophthalmol,2011

4. Antivascular endothelial growth factors in age-related macular degeneration.;Schmidt-Erfurth;Dev Ophthalmol,2010

5. Ranibizumab for neovascular age-related macular degeneration.;Rosenfeld;N Engl J Med,2006

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting delivery and therapies for neovascular age-related macular degeneration;Expert Opinion on Biological Therapy;2024-07-22

2. Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity;International Ophthalmology;2024-07-02

3. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits;Pharmaceutical Research;2024-06

4. Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2023-10

5. Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion;Scientific Reports;2023-07-26